|
BioLineRx Ltd.
|
|
|
|
|
|
|
By:
|
/s/ Philip Serlin
|
|
|
|
|
Philip Serlin
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
1.
|
To re-elect the following persons to the Board of Directors, each to serve until the next Annual General Meeting of shareholders: Aharon Schwartz, Michael Anghel, B.J. Bormann, Raphael
Hofstein and Sandra Panem.
|
|
2.
|
With respect to the employment terms of Philip Serlin, the Company’s Chief Executive Officer, to approve the following:
a. approve amendments to the termination provisions of Mr. Serlin’s employment agreement; and
b. reduce the exercise price of certain options to purchase ordinary shares held by Mr. Serlin.
|
|
3.
|
To approve an increase in the number of the Company’s authorized ordinary shares and authorized share capital, and to amend the Articles of Association of the Company to reflect such
increase.
|
4.
|
To reappoint Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent registered public
accounting firm for the year ending December 31, 2020 and to authorize the Audit Committee of the Board of Directors to fix the compensation of said auditors in accordance with the scope and nature of their services.
|
5.
|
To review the Company’s Annual Report and financial statements for the year ended December 31, 2019, and to transact such other business as may properly come before the Meeting.
|
•
|
the majority of shares that voted for the approval of the respective proposal includes at least a majority of the shares held by non-controlling and non-interested shareholders voted at the
Meeting (excluding abstaining votes) and via the ISA Electronic Voting System; or
|
•
|
the total number of shares of non-controlling and non-interested shareholders that voted against the approval of the respective proposal does not exceed two percent of the aggregate voting
rights in the company (“Disinterested Majority”).
|
Director
|
Age
|
Principal Occupation
|
Aharon Schwartz, Ph.D.
|
77
|
Dr. Schwartz has served as the Chairman of our Board of Directors since 2004. He served in a number of positions in Teva from 1975 through 2011, the most recent being Vice President, Head of
Teva Innovative Ventures from 2008. Dr. Schwartz is currently a member of the board of directors of Protalix Ltd. (NYSE American:PLX), and Barcode Ltd. He also works as an independent consultant. Dr. Schwartz received his Ph.D. in organic
chemistry from the Weizmann Institute, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. In addition, Dr. Schwartz holds a Ph.D. from the Hebrew University of
Jerusalem in the history and philosophy of science.
|
Michael Anghel, Ph.D.
|
81
|
Dr. Anghel has served on our Board of Directors since 2010 and on our Investment Monitoring Committee since 2010. From 1977 to 1999, he led the Discount Investment Corporation Ltd. (of the
IDB Group) activities in the fields of technology and communications. Dr. Anghel was instrumental in founding Tevel, one of the first Israeli cable television operators and later in founding Cellcom Israel Ltd. (NYSE:CEL), the second Israeli
cellular operator. In 1999, he founded CAP Ventures, an advanced technology investment company. From 2004 to 2005, Dr. Anghel served as CEO of DCM, the investment banking arm of the Israel Discount Bank (TASE:DSCT). Over the years, Dr. Anghel
has been involved in founding and managing various technology enterprises and has served on the Boards of Directors of various major Israeli corporations and financial institutions, many of them publicly traded in the U.S. and Israel. During
the past two years, he completed long term tenures as director on the boards of: Partner Communications Company, Ltd. (Nasdaq:PTNR, TASE:PTNR), Strauss Group Ltd. (TASE:STRS), and Orbotech Ltd. (Nasdaq:ORBK), He currently serves as director
on the boards of InMode Ltd. (Nasdaq:INMD) and Ellomay Capital Ltd. (NYSE American: ELLO). Prior to launching his business career, Dr. Anghel served as a full-time member of the faculty of the Recanati Graduate School of Business
Administration of the Tel Aviv University, where he taught finance and corporate strategy. He currently serves as Chairman of the Tel Aviv University’s Executive Program. Dr. Anghel holds a B.A. (Economics) from the Hebrew University in
Jerusalem and an MBA and Ph.D. (Finance) from Columbia University, New York.
|
B.J. Bormann, Ph.D.
|
61
|
Dr. Bormann has served on our Board of Directors since August 2013. Dr. Bormann currently serves as the Vice President of Translational Science and Network Alliances at The Jackson
Laboratory, a non-profit organization focused on the genetic basis of disease. Dr. Bormann was previously the Chief Executive Officer of Supportive Therapeutics, LLC, a Boston based company that is developing two molecules for use in the
supportive care of oncology patients. In the past several years Dr. Bormann has held executive positions in several biotechnology companies including NanoMedical Systems (Austin, Texas), Harbour Antibodies (Rotterdam, The Netherlands) and
Pivot Pharmaceuticals (PVTF: OTC listed). Prior to these engagements, Dr. Bormann was Senior Vice President responsible for world-wide alliances, licensing and business development at Boehringer Ingelheim Pharmaceuticals, Inc. from 2007 to
2013. From 1996 to 2007, she served in a number of positions at Pfizer, Inc., the last one being Vice President of Pfizer Global Research and Development and world-wide Head of Strategic Alliances. Dr. Bormann serves on the board of directors
of various companies, including Xeris Pharmaceuticals, Inc (Nasdaq:XERS). Dr. Bormann received her Ph.D. in biomedical science from the University of Connecticut Health Center and her B.Sc. from Fairfield University in biology. Dr. Bormann
completed postdoctoral training at Yale Medical School in the department of pathology.
|
Raphael Hofstein, Ph.D.
|
70
|
Dr. Hofstein has served on our Board of Directors since 2003, our Audit Committee since 2007 and our Compensation Committee since 2012. Dr. Hofstein has served as the President and Chief
Executive Officer of MaRS Innovation (a commercialization company for 15 of Toronto’s universities, institutions and research institutes plus the MaRS Discovery District) from June 2009 to March 2020. From 2000 through June 2009, Dr. Hofstein
was the President and Chief Executive Officer of Hadasit Medical Research Services and Development Ltd., or Hadasit, the technology transfer company of Hadassah University Hospitals. He has served as chairman of the board of directors of
Hadasit since 2006. Prior to joining Hadasit, Dr. Hofstein was the President of Mindsense Biosystems Ltd. and the Business Unit Director of Ecogen Inc. and has held a variety of other positions, including manager of R&D and chief of
immunochemistry at the International Genetic Science Partnership. Dr. Hofstein serves on the board of directors of numerous companies. Dr. Hofstein received his Ph.D. and M.Sc. from the Weizmann Institute of Science, and his B.Sc. in
chemistry and physics from the Hebrew University in Jerusalem. Dr. Hofstein completed postdoctoral training at Harvard Medical School in both the departments of biological chemistry and neurobiology.
|
Sandra Panem, Ph.D.
|
73
|
Dr. Panem has served on our Board of Directors since February 2014. She is currently a managing partner at Cross Atlantic Partners, which she joined in 2000. She is also co-founder and
President of NeuroNetworks Fund, a not-for-profit venture capital fund focusing on epilepsy, schizophrenia and autism. From 1994 to 1999, Dr. Panem was President of Vector Fund Management, the then asset management affiliate of Vector
Securities International. Prior thereto, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private biotechnology companies. Previously, she was Vice
President at Salomon Brothers Venture Capital, a fund focused on early and later-stage life sciences and technology investments. Dr. Panem was also a Science and Public Policy Fellow in economic studies at the Brookings Institution, and an
Assistant Professor of Pathology at the University of Chicago. Dr. Panem currently serves on the board of directors of Acorda Therapeutics, Inc. (Nasdaq:ACOR). Previously, Dr. Panem served on numerous boards of public and private companies,
including Martek Biosciences (Nasdaq:MATK), IBAH Pharmaceuticals (Nasdaq:IBAH), Confluent Surgical, Molecular Informatics and Labcyte, Inc. She received a B.S. in biochemistry and a Ph.D. in microbiology from the University of Chicago.
|
-BIOLINERX LTD.
For the Annual General Meeting of Shareholders
to be held on September 24, 2020 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
|
||
The undersigned shareholder of BioLineRx Ltd. (the “Company”) hereby appoints Mali Ze’evi and/or Raziel Fried, and each or either of them, the true and
lawful attorney, agent and proxy of the undersigned, with full power of substitution, to vote, as designated below, all of the ordinary shares of the Company which the undersigned is entitled in any capacity to vote at the Annual General
Meeting of the shareholders of the Company which will be held at the offices of the Company at Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel, on September 24, 2020 at 3:00 p.m. (local time), and all adjournments and
postponements thereof.
|
||
(CONTINUED AND TO BE SIGNED ON REVERSE SIDE)
|
See
Reverse
Side
|
|
|
THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED HEREIN.
IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED “FOR” THE PROPOSALS HEREIN.
|
||||
|
Please mark your vote for the following resolutions as in this example ☒
|
|
|||
|
|
|
|
|
|
1.
|
TO RE-ELECT the following nominees to serve as directors of the Company for the coming year until the next annual general meeting of the Company’s shareholders or until their respective
successors are duly elected:
|
FOR
|
AGAINST
|
ABSTAIN
|
|
|
a. Aharon Schwartz
|
☐
|
☐
|
☐
|
|
|
b.Michael Anghel
|
☐
|
☐
|
☐
|
|
|
c. B.J. Bormann
|
☐
|
☐
|
☐
|
|
|
d. Raphael Hofstein
|
☐
|
☐
|
☐
|
|
|
e. Sandra Panem
|
☐
|
☐
|
☐
|
|
|
|
|
|
|
2.
|
TO APPROVE amendments to the employment terms of Philip Serlin, the Company’s Chief Executive Officer, all as described in the Proxy Statement.
Do you have a “Personal Interest” (as defined in the Proxy Statement) with respect to the subject matter of this proposal? (Please note: if you do not mark
either “Yes” or “No” your shares will not be voted on Proposal 2)
|
FOR
☐
Yes
☐
|
AGAINST
☐
No
☐
|
ABSTAIN
☐
|
|
|
|
|
|
|
|
3.
|
TO APPROVE an increase in the Company’s registered share capital from NIS 50,000,000 divided into 500,000,000 ordinary shares of a nominal value of NIS 0.10 each to NIS 150,000,000 divided
into 1,500,000,000 ordinary shares of a nominal value of NIS 0.10 each, and a corresponding amendment to Article 4.1 of the Company’s Articles of Association.
|
FOR
☐
|
AGAINST
☐
|
ABSTAIN
☐
|
Name: __________________________________
Number of shares:_________________________
Signature: _______________________________
Date: ___________________________________
NOTE: Please mark date and sign exactly as the name(s) appear on this proxy. If the signer is a corporation, please sign the full corporate name by a
duly authorized officer. Executors, administrators, trustees, etc. should state their full title or capacity. Joint owners should each sign.
|
|
|
|
|
|
|
4.
|
TO RE-APPOINT Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limitedd, as the independent public auditors of the Company for the year ending December 31, 2020
and to authorize the Audit Committee of the Board of Directors to fix the compensation of said auditors in accordance with the scope and nature of their services.
|
FOR
☐
|
AGAINST
☐
|
ABSTAIN
☐
|
1.
|
Please direct the Depositary how it is to vote by placing an “X” in the appropriate box opposite each agenda item. It is understood that, if this form is signed and
returned but no instructions are indicated in the boxes, then a discretionary proxy will be given to a person designated by the Company.
|
2.
|
It is understood that, if this form is not signed and returned, the Depositary will deem such holder to have instructed the Depositary to give a discretionary proxy
to a person designated by the Company.
|
|
MAIL
|
• Mark, sign and date your Voting Instruction Form.
• Detach your Voting Instruction Form.
• Return your Voting Instruction Form in the postage-paid envelope provided.
|
PROXY TABULATOR FOR
BIOLINERX LTD.
P.O. BOX 8016
CARY, NC 27512-9903
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
EVENT #
|
|
|
|
|
|
|
|
|
|
|
|
CLIENT #
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
|
September 24, 2020
|
See Voting Instruction On Reverse Side.
|
1. |
TO RE-ELECT the following nominees to serve as directors of the Company for the coming year until the next annual general meeting of the Company’s shareholders or until their respective
successors are duly elected:
|
||||
For | Against |
Abstain | |||
|
a. |
Aharon Schwartz
|
☐ |
☐
|
☐
|
|
b. | Michael Anghel |
☐
|
☐
|
☐
|
|
c. | B.J. Bormann |
☐
|
☐
|
☐
|
|
d. | Raphael Hofstein |
☐
|
☐
|
☐
|
|
e. | Sandra Panem |
☐
|
☐
|
☐
|
2. |
TO APPROVE amendments to the employment terms of Philip Serlin, the Company’s Chief Executive Officer, all as described in the Proxy Statement.
|
☐
|
☐
|
☐
|
|
Yes
|
No |
||||
|
2a. |
Do you have a “Personal Interest” (as defined in the Proxy Statement) with respect to the subject matter of this proposal? (Please note: if you
do not mark either “Yes” or “No” your shares will not be voted on Proposal 2)
|
☐
|
☐
|
|
|
|
|
For | Against | Abstain |
3. |
TO APPROVE an increase in the Company’s registered share capital from NIS 50,000,000 divided into 500,000,000 ordinary shares of a nominal value
of NIS 0.10 each to NIS 150,000,000 divided into 1,500,000,000 ordinary shares of a nominal value of NIS 0.10 each, and a corresponding amendment to Article 4.1 of the Company’s Articles of Association.
|
☐ | ☐ |
☐ |
|
4. |
TO RE-APPOINT Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limitedd, as the independent public auditors of the
Company for the year ending December 31, 2020 and to authorize the Audit Committee of the Board of Directors to fix the compensation of said auditors in accordance with the scope and nature of their services.
|
☐ |
☐ | ☐ |
|
|
|
Please Sign Here
|
|
Please Date Above
|
|
|
|
Please Sign Here
|
Please Date Above
|